Welcome to our dedicated page for Adaptimmune Therapeutics news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics plc reports corporate and business developments for its ADSs and engineered T-cell therapy operations in solid tumor cancers. News has covered financial results, TECELRA commercial updates, cell therapy asset transactions, debt repayment, restructuring activity, and remaining programs directed at PRAME and CD70.
Company updates also address Nasdaq listing matters, ADS trading status, deregistration actions, executive changes, and conference participation. Adaptimmune’s disclosed business context centers on its engineered T-cell receptor platform, personalized cell therapies, and the corporate transition following the completed transfer of TECELRA, lete-cel, afami-cel, and uza-cel assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Technavio reports that the global gene therapy market is projected to grow by USD 4,613.9 million from 2022 to 2027, at a CAGR of 19.91%. This growth is fueled by increasing special drug designations such as orphan, fast track, and breakthrough designations by regulatory bodies, enhancing market opportunities. The oncology segment will see significant growth due to the unmet demand for cancer treatments. North America is expected to contribute 39% to the market growth, supported by government funding for gene therapy research. However, high treatment costs, ranging from USD 1 million to 3 million, present a major challenge.
The gene therapy market is projected to grow by $4.61 billion from 2023 to 2027, with a CAGR of 19.91%. This growth is attributed to increasing special drug designations, benefits of gene therapy, and rising chronic diseases prevalence.
The market report analyzes key areas including market size, trends, growth drivers, and challenges, covering around 25 vendors. The report segments the market by therapy areas like oncology, CNS, and rare diseases, along with delivery modes and geography.
Key vendors include Adaptimmune Therapeutics (ADAP) and Orchard Therapeutics (ORTX), among others.
The report titled "Global TCR Therapy Market, 2022-2035" outlines significant growth prospects in TCR-based therapies, with an annual growth rate of 51% expected over the next decade. This emerging class of adoptive therapy targets specific tumor markers using genetically modified T-cells, showing efficacy primarily in hematological and solid tumors. The FDA's approval of Kimmtrak for treating metastatic uveal melanoma in January 2022 marks a milestone in the market. The market is projected to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma, with over 90% of therapy candidates being autologous.
ReCode Therapeutics has established a scientific advisory board (SAB) to enhance its genetic medicine pipeline, led by Daniel J. Siegwart. The SAB includes experts such as Rafael Amado and Carrolee Barlow, who bring extensive experience in drug development and delivery technology. This initiative aims to advance their selective organ targeting (SORT) lipid nanoparticle platform and accelerate programs for conditions like primary ciliary dyskinesia and cystic fibrosis to enter clinical stages in 2023.
Alnylam Pharmaceuticals has appointed Dr. Elliott Sigal to its Board of Directors, enhancing its leadership at a pivotal moment. With decades of experience, including his role as Chief Scientific Officer at Bristol-Myers Squibb, Dr. Sigal contributed to the launch of 14 new medicines across various therapeutic areas. His expertise is expected to strengthen Alnylam's ongoing efforts in advancing RNAi therapeutics aimed at rare diseases. The company continues its pursuit of transforming healthcare through innovative treatments, guided by its 'Alnylam P5x25' strategy.